Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 7/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20783989 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL26715276 | 0.83 | MAPKAPK2 (0.71) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL15639981 | 0.82 | KDR (0.55) | MAPKAPK2KDRROCK2ROCK1 | |
| SCHEMBL31351684 | 0.82 | KDR (0.50) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL26717703 | 0.80 | MAPKAPK2 (0.67) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL6606097 | 0.80 | MAPKAPK2 (0.67) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL20612442 | 0.80 | KDR (0.60) | MAPKAPK2KDRROCK2ROCK1 | |
| SCHEMBL16638038 | 0.80 | ROCK2 (0.61) | MAPKAPK2KDRROCK2ROCK1 | |
| SCHEMBL18114560 | 0.79 | ROCK2 (0.71) | MAPKAPK2KDRROCK2ROCK1 | |
| SCHEMBL10049851 | 0.79 | EGFR (0.53) | MAPKAPK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| CN-114105976-B | Selective ROCK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4155308-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| EP-2154967-A1 | PYRIMIDINE DERIVATIVES | Hutchison Medipharma Enterprises Limited (BS) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | MAPKAPK2 3124/4885KDR 2/4885ROCK2 723/4885 |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, ROCK2, RHOT2 | MAPKAPK2 40/4885KDR 1047/4885ROCK2 2/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | MAPKAPK2 662/4885KDR 3466/4885ROCK2 1/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | MAPKAPK2 46/4885KDR 2544/4885ROCK2 2/4885 |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | TYMS, KDR, FLT4 | MAPKAPK2 4031/4885KDR 2/4885ROCK2 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.